Literature DB >> 22341352

Transplantation of Cbfa1-overexpressing adipose stem cells together with vascularized periosteal flaps repair segmental bone defects.

Jianjun Li1, Qun Zhao, Enbo Wang, Chuanhui Zhang, Guangbin Wang, Quan Yuan.   

Abstract

BACKGROUND: Segmental bone defect is still a challenge to orthopedic surgeons. Currently available therapies for segmental bone defects have some drawbacks. Tissue engineering using pluripotent stem cells is a new, promising method for bone repair. The present study aims to promote the effect of bone defect repair using the tissue engineered bone in combination with vascularized periosteal flaps.
METHODS: The adenoviral vector carrying Cbfa1 transduced rabbit adipose-derived mesenchymal stem cells and gene modified tissue engineering bone (GMB) were constructed. Rabbits with radial defects were implanted with the GMB together with vascularized periosteum (group A); or GMB with free periosteum (group B); or GMB (group C), and scaffold (group D). The bone repair effect was evaluated at 4, 8, or 12 wk, respectively, after the operations.
RESULTS: Cbfa1 proteins were strongly expressed in adipose stem cells (ADSCs) that formed a stratified network on the inner surface of the polylactic acid/ polycaprolacton (PLA/PCL) pores. Bone repair was well achieved in the rabbits treated with the Cbfa1-expressing ADSCs and vascularized flap that was markedly better than those treated with either Cbfa1-expressing ADSCs alone or with vascularized flap alone.
CONCLUSIONS: Combination with implanting the Cbfa1 gene-modified tissue-engineered bone and vascularized periosteum can better repair the segmental bone defects by stimulating osteogenesis, osteoinduction, and osteoconduction than using either one of the approaches.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22341352     DOI: 10.1016/j.jss.2011.12.011

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  8 in total

Review 1.  Current Trends in Viral Gene Therapy for Human Orthopaedic Regenerative Medicine.

Authors:  Jagadeesh Kumar Venkatesan; Ana Rey-Rico; Magali Cucchiarini
Journal:  Tissue Eng Regen Med       Date:  2019-02-21       Impact factor: 4.169

2.  The osteogenic study of tissue engineering bone with BMP2 and BMP7 gene-modified rat adipose-derived stem cell.

Authors:  Wang Qing; Chen Guang-Xing; Guo Lin; Yang Liu
Journal:  J Biomed Biotechnol       Date:  2012-06-21

3.  Effect of CGRP-adenoviral vector transduction on the osteoblastic differentiation of rat adipose-derived stem cells.

Authors:  Zhong Fang; Qin Yang; Wei Xiong; Guang-hui Li; Hui Liao; Jun Xiao; Feng Li
Journal:  PLoS One       Date:  2013-08-30       Impact factor: 3.240

4.  Mesenchymal stem cells overexpressing Ihh promote bone repair.

Authors:  Shasha Zou; Tingting Chen; Yanan Wang; Ruhui Tian; Lingling Zhang; Pingping Song; Shi Yang; Yong Zhu; Xizhi Guo; Yiran Huang; Zheng Li; Lixin Kan; Hongliang Hu
Journal:  J Orthop Surg Res       Date:  2014-10-28       Impact factor: 2.359

Review 5.  Ordinary and Activated Bone Grafts: Applied Classification and the Main Features.

Authors:  R V Deev; A Y Drobyshev; I Y Bozo; A A Isaev
Journal:  Biomed Res Int       Date:  2015-11-15       Impact factor: 3.411

6.  Use of stem-cell sheets expressing bone morphogenetic protein-7 in the management of a nonunion radial fracture in a Toy Poodle.

Authors:  Jaeyong Song; Yongsun Kim; Oh-Kyeong Kweon; Byung-Jae Kang
Journal:  J Vet Sci       Date:  2017-12-31       Impact factor: 1.672

7.  Immunohistochemical and molecular characterization of the human periosteum.

Authors:  Sönke Percy Frey; Hendrik Jansen; Stefanie Doht; Luis Filgueira; Rene Zellweger
Journal:  ScientificWorldJournal       Date:  2013-05-02

Review 8.  Adipose-derived mesenchymal cells for bone regereneration: state of the art.

Authors:  Marta Barba; Claudia Cicione; Camilla Bernardini; Fabrizio Michetti; Wanda Lattanzi
Journal:  Biomed Res Int       Date:  2013-11-07       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.